Author:
Luo Jingran,Chang Xinxin,Wang Suri Yuqing,Yu Hongchuan
Abstract
Monoclonal antibody-based therapy is a promising strategy to treat breast cancer because, as a targeted cancer drug, it locates and binds to a specific cancer cell. The importance of monoclonal antibodies to give an additional and efficient channel remains a serious issue because several kinds of breast cancer, particularly Triple-negative breast cancer (TNBC), have limited methods and a low response to conventional drug therapy. Although patients associated with metastatic diseases used to experience short survival and poor prognosis, developments have been achieved recently. The development of targeted cancer drugs is thought to improve clinical therapies for breast cancers and the overall survival length of patients. Expectations are that targeted cancer drugs will be pair used with chemotherapy, and data has already shown that patients lived nearly two times longer compared to before. This review provides an overview of three types of monoclonal antibodies, trastuzumab, pertuzumab, and trodelvy (sacituzumab govitecan) respectively, which all act as targeted cancer drugs in breast cancer treatments. Three main parts are included in this review, involving the historical development of the drugs, the mechanism of the drugs, and the issues of the drugs while being utilized to treat breast cancer, which is separated into two parts: the side effects and drug resistance.
Publisher
Darcy & Roy Press Co. Ltd.
Reference24 articles.
1. Ullrich, A., et al. (1984). Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature, 309(5967), 418–425.
2. Faratian, D., et al. (2011). Trastuzumab and pertuzumab produce changes in morphology and estrogen receptor signaling in ovarian cancer xenografts revealing new treatment strategies. Clinical Cancer Research, 17(13), 4451-4461.
3. (2006). Clinical activity of pertuzumab (rhumab 2c4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. Journal of Clinical Oncology Official Journal of the American Society of Clinical Oncology, 24(26), 4324.
4. World Health Organization (2015). "International nonproprietary names for pharmaceutical substances (INN): proposed INN: list 113". WHO Drug Information. 29 (2): 260–1.
5. Bardia A, et al. (2019). "Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer". The New England Journal of Medicine. 380 (8): 741–751.